Nationwide Hospitals Invited — Recruitment Officially Launched for the 'Real-World Multi-Center Study of Methylation Testing in Cervical Cancer Screening'
[Foreword]
With the rapid development of molecular detection in gynecologic oncology screening, methylation detection of tumor target genes such as PAX1/JAM3 has demonstrated significant value in triaging HPV-positive populations and improving CIN2+ detection rates. In recent years, the publication of the WHO Cervical Cancer Screening Guidelines (2nd Edition) and multiple Chinese cervical cancer screening guidelines and expert consensus statements have provided strong guideline-level and academic support for the clinical adoption of methylation testing. Our prior work includes multiple clinical cohorts, clinical trials, and academic publications (several SCI-indexed), along with large-scale real-world data collection, laying the foundation for this multicenter study.
I. Study Highlights and Compliance Information (Summary)
- Study Name: Multicenter Real-World Study of Methylation Testing for Gynecologic Tumor Screening
- Lead Institution: Li Lei's team, Department of Obstetrics and Gynecology, Gynecologic Oncology Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; National Key Laboratory of Rare and Severe Diseases.
- Data Collection: Participant demographics, cytology, HPV genotyping, PAX1/JAM3 dual-gene methylation testing, etc.
II. Recruitment Criteria
Class III Grade A hospitals, regional hospitals, and community medical institutions nationwide with the capacity to conduct cervical cancer screening and triage are welcome to apply. Institutions with ethical review and data management capabilities are encouraged to participate.
III. Collaboration Process (Main Steps)
- Data collection in accordance with national clinical research regulations;
- Participating institutions review the study protocol and assess feasibility;
- Sign the collaborative research agreement;
- Clinical data collection;
- Periodic online working meetings (study progress, quality control, methodological discussions);
- Final large-scale statistical analysis and joint publication of academic papers and research reports.
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.